|
|
Article: Antares Pharma Announces Notice of Allowance for Newest ATD(TM) Gel Patent.
- Article from:
- Business Wire
- Article date:
- February 21, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EWING, N.J. -- Antares Pharma, Inc. (Amex:AIS) announced receipt of Notice of Allowance from the United States Patent & Trademark Office (USPTO) covering semi-solid pharmaceutical compositions used in its Advanced Transdermal Delivery (ATD[TM]) technology. The USPTO has stated that it intends to grant patent protection which covers hormonal and non-hormonal formulations developed by Antares Pharma. The patent is expected to issue mid-year and will remain in force until 2021.
This new patent may also provide Antares Pharma with the necessary protection in the field of non-occlusive transdermal delivery of non-hormonal drug products. Anturol[TM], Antares' principal ...